Actively Recruiting
Study of Polatuzumab, Bendamustine, and Rituximab Treatment for Relapsed or Refractory Mantle Cell Lymphoma in Adults
Led by Medical University of Vienna · Updated on 2024-05-29
16
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research investigates the effectiveness of a combination treatment using polatuzumab vedotin, bendamustine, and rituximab in patients with mantle cell lymphoma that has returned or did not respond to previous therapy. The study is a single-center Phase II trial led by the Medical University of Vienna, focusing on patients who have relapsed or refractory mantle cell lymphoma after standard first-line chemotherapy including ibrutinib. The primary goal is to measure the objective response rate using RECIST 1.1 criteria. Participants receive polatuzumab vedotin intravenously at 1.8 mgkg on day 2 of the first cycle, then on day 1 of each following 21-day cycle. Bendamustine is given intravenously at 90 mgm2 on days 2 and 3 of the first cycle, and on days 1 and 2 of subsequent cycles. Rituximab is administered intravenously at 375 mgm2 on day 1 of each cycle. Patients may receive up to six cycles of this combination treatment. Throughout the study, participants will be closely monitored for their response to treatment, survival, and any side effects or toxicities. The main outcome measure is the objective response rate assessed from enrollment until the first progression, death, or treatment discontinuation, for up to 36 months. Safety and survival are also tracked during this period. The total participation includes regular infusions and evaluations over the course of treatment cycles and follow-up assessments.
CONDITIONS
Brief Title
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Research Team
B
Barbara Kiesewetter, MD
M
Marika Rosner
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here